文献速递造血干细胞移植与细胞治疗淋巴瘤

嵌合抗原受体T细胞安全性:药物警戒与荟萃分析研究

Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
PubMed 文献 · Am J Hematol · 2021-06-23

该研究通过WHO VigiBase数据库的药物警戒分析和文献荟萃分析,评估靶向CD19的CAR-T细胞(阿基仑赛、替沙仑赛)相关不良药物反应。识别出9类不良事件,细胞因子释放综合征最常见(n=1378)。不良事件相关死亡占5.5%,主要与噬血细胞性淋巴组织细胞增生症、脑血管病、感染和呼吸衰竭相关。

要点

  • CAR-T相关不良事件涉及9大类,以细胞因子释放综合征、神经系统和血液学紊乱最常见。
  • 不良事件相关死亡占5.5%,与噬血细胞性淋巴组织细胞增生症、感染和器官衰竭相关。
  • 输注后一周内可能发生严重不良事件,但罕见致命,需重点监测感染和器官功能。

核心结论

  • CAR-T与9类不良药物反应相关,细胞因子释放综合征最常见,不良事件相关死亡占5.5%。

研究设计与样本

  • 观察性横断面药物警戒队列研究,分析WHO VigiBase数据库个例安全报告,并对截至2020年3月的CAR-T试验和队列进行荟萃分析。

主要发现

  • 细胞因子释放综合征n=1378(IC025=4.24),神经系统疾病n=963(IC025=2.42),血液学疾病n=532(IC025=3.32)。
  • 感染n=287(IC025=2.38),心血管疾病n=256(IC025=2.81),肺部疾病n=186(IC025=3.80)。
  • 代谢与肾脏疾病n=123(IC025=1.89),噬血细胞性淋巴组织细胞增生症n=36(IC025=5.01),肝脏疾病n=32(IC025=2.49)。
  • 不良事件相关死亡99/1783(5.5%),全因死亡262/1783(14.7%)。
  • 荟萃分析中任何级别最常见不良事件为细胞因子释放综合征、血液学疾病和神经系统疾病;致命不良事件最常见于神经系统疾病、细胞因子释放综合征和感染。

临床怎么用

  • 输注后一周内重点监测细胞因子释放综合征和神经系统事件。
  • 对感染、噬血细胞性淋巴组织细胞增生症及神经或肺部等终末器官衰竭保持高度警惕。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric-antigen-receptor T cells directed against CD19 (CAR-T) are emerging hematological therapeutics with scarce data on its overall safety profile spectrum. To determine the clinical features and incidence of adverse-drug reactions (ADR) associated with CAR-T. This observational, cross-sectional, pharmacovigilance cohort study examined individual case safety reports from the World Health Organization database VigiBase and meta-analysis of data from CAR-T trials and cohorts in the literature was also performed through March, 2020. The primary objective was to identify ADR associated with approved CAR-T (axicabtagene-ciloleucel; tisagenlecleucel). We conducted a Bayesian disproportionate analysis with the 95% lower credibility-interval of information component (IC025 , significance > 0). We also performed a systematic-review and meta-analysis of CAR-T trials and cohorts in the literature to evaluate ADR incidence. Nine ADR classes were associated with CAR-T: Cytokine release syndrome (CRS, n = 1378, IC025 = 4.24), neurological disorders (n = 963, IC025 = 2.42), hematological disorders (n = 532, IC025 = 3.32), infections (n = 287, IC025 = 2.38), cardiovascular disorders (n = 256, IC025 = 2.81), pulmonary disorders (n = 186, IC025 = 3.80), reno-metabolic disorders (n = 123, IC025 = 1.89), hemophagocytic-lymphohistiocytosis (n = 36, IC025 = 5.01) and hepatic disorders (n = 32, IC025 = 2.49). ADR-related fatalities accounted for 99/1783 (5.5%) of the reports and 262/1783 (14.7%) for all-cause mortality. These ADR-related fatalities were associated with hemophagocytic-lymphohistiocytosis, cerebral vascular disorder, infections, and respiratory failure. In meta-analyses, the most frequent any-grade ADRs were CRS, hematological disorders, and neurological disorders. Fatal ADR were most found with neurological disorders, CRS, and infections. Note, CAR-T infusion may be associated with severe ADR mainly following the week of administration, though rarely fatal. Infections, hemophagocytic-lymphohistiocytosis and end organ failures including neurological or lung involvements require scrutiny.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Dolladille C, Ederhy S, Ezine E, et al. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study. Am J Hematol. 2021. PMID: 34057232. doi:10.1002/ajh.26259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。